Mike Ufer
Overview
Explore the profile of Mike Ufer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
795
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brimhall D, Chen Y, Lee S, Yoshida K, Ufer M
Pharmacol Res Perspect
. 2025 Jan;
13(1):e70067.
PMID: 39887952
Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the...
2.
Abbara A, Ufer M, Voors-Pette C, Berman L, Ezzati M, Wu R, et al.
Fertil Steril
. 2023 Nov;
121(1):95-106.
PMID: 37925096
Background: Kisspeptin is an essential regulator of hypothalamic gonadotropin-releasing hormone release and is required for physiological ovulation. Native kisspeptin-54 can induce oocyte maturation during in vitro fertilization treatment, including in...
3.
Boof M, Ufer M, Fietze I, Pepin J, Guern A, Lemoine V, et al.
Sleep Med
. 2022 Mar;
92:4-11.
PMID: 35306405
Background: The dual orexin receptor antagonist daridorexant did not impact nighttime respiratory function as assessed by the apnea/hypopnea index (AHI) and nocturnal oxygen saturation (SpO) and improved sleep in patients...
4.
Zenklusen I, Hsin C, Schilling U, Kankam M, Krause A, Ufer M, et al.
Clin Pharmacokinet
. 2021 Dec;
61(5):687-695.
PMID: 34961905
Background And Objectives: Selatogrel is a potent, reversible, and selective antagonist of the platelet P2Y receptor currently developed for the treatment of acute myocardial infarction (AMI). In the completed Phase...
5.
Ufer M, Kelsh D, Schoedel K, Dingemanse J
Sleep
. 2021 Sep;
45(3).
PMID: 34480579
Study Objectives: Abuse potential properties have been reported for the dual orexin receptor antagonists (DORAs) suvorexant and lemborexant. Daridorexant is a new DORA currently in late-stage clinical development. This randomized,...
6.
Schilling U, Henrich A, Muehlan C, Krause A, Dingemanse J, Ufer M
Clin Drug Investig
. 2021 Jul;
41(8):711-721.
PMID: 34331678
Background And Objective: Daridorexant is a new dual orexin receptor antagonist currently in late-stage clinical development for the treatment of insomnia. This randomized, double-blind, placebo-controlled, four-period crossover study investigated the...
7.
Juif P, Dingemanse J, Ufer M
Front Pharmacol
. 2021 Feb;
11:628956.
PMID: 33613288
Aneurysmal subarachnoid hemorrhage (aSAH) may lead to cerebral vasospasm and is associated with significant morbidity and mortality. It represents a major unmet medical need due to few treatment options with...
8.
Boof M, Dingemanse J, Brunke M, Esselmann A, Heymer P, Kestermann O, et al.
J Sleep Res
. 2021 Jan;
30(4):e13248.
PMID: 33417730
In patients with chronic obstructive pulmonary disease (COPD), sleep is often fragmented while, conversely, the use of sleep medications is of concern in these patients due to potential impairment of...
9.
Schilling U, Dingemanse J, Dobrow M, Baumann M, Riederer M, Juif P, et al.
Thromb Haemost
. 2021 Jan;
121(6):755-766.
PMID: 33412611
Reduced pharmacodynamic (PD) effects of irreversible oral P2Y receptor antagonists have been reported when administered during cangrelor infusion. Therefore, the PD interaction liability of the novel P2Y receptor antagonist selatogrel...
10.
Huynh C, Henrich A, Strasser D, Boof M, Al-Ibrahim M, Zu Schwabedissen H, et al.
Clin Pharmacol Ther
. 2021 Jan;
109(6):1648-1659.
PMID: 33406277
The C-X-C chemokine receptor 7 (CXCR7) has evolved as a promising, druggable target mainly in the immunology and oncology fields modulating plasma concentrations of its ligands CXCL11 and CXCL12 through...